Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Biotech

CAR-T pioneer on riding the NIH roller coaster, speaking up for science, and his funder Sean Parker

By Elizabeth Cooney

Biotech

Patients in landmark genome-editing trial show improvement — but with questions over whether the therapy did the trick

By Adam Feuerstein

Lessons Learned

Lessons Learned: This is how you go from clinical practice to a startup

By Megha Satyanarayana

Business

Agios Pharma names a new CEO, one with commercial chops in biotech

By Adam Feuerstein

Biotech

China is poised to approve its first innovative homegrown drug for a common cancer. Next stop? The U.S.

By Rebecca Robbins

Biotech

First CRISPR clinical trial backed by U.S. companies launches

By Sharon Begley

The Readout LOUD

LISTEN: FDA shows its teeth, biotech fish oil might be pointless, & the quest to cure McCain’s cancer

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

In the Lab

CRISPR fixed Duchenne muscular dystrophy in beagles. Will this technique overtake an older gene therapy?

By Sharon Begley

Adam's Take

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

By Adam Feuerstein

Biotech

The IPO boom has been particularly kind to biotech in Massachusetts

By Jonathan Saltzman — Boston Globe and Kate Sheridan — STAT

Biotech

Genealogist Barbara Rae-Venter helped crack the Golden State Killer case. And yes, that last name is familiar

By Rebecca Robbins

Adam's Take

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

By Adam Feuerstein

Paula Soteropoulos, CEO of Akcea Therapeutics.

Biotech

FDA rejects Akcea rare-disease drug that uses gene-blocking technology

By Kate Sheridan

Business

Relief rally! Alnylam shares higher as Pfizer heart disease drug leaves room for competition

By Adam Feuerstein

Biotech

Negative fish oil study results raise the stakes for Amarin’s capsule

By Adam Feuerstein

Pharmalot

Pharmalittle: FDA eyes side-effect lists in drug ads; generic Paxil verdict tossed

By Elizabeth Cooney

Biotech

Don’t say ‘disrupt’ and other red flags when pitching to a venture capitalist

By Rebecca Robbins and Damian Garde

The Readout LOUD

LISTEN: A genome-editing first, Trump on Wall Street, and biotech red flags

By Damian Garde and Rebecca Robbins

Pharmalot

Pharmalittle: Pharma groups warn Saudis; Medicare struggles over CAR-T

By Elizabeth Cooney

Opinions Plus

Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros

By Elizabeth Cooney

Biotech

Could eating bioengineered bacteria with every meal treat a serious disease?

By Karen Weintraub

Biotech

At Silicon Valley’s debutante ball for startups, there’s more biology than ever

By Rebecca Robbins

Lessons Learned

Lessons Learned: Here’s how a scientist became a serial entrepreneur

By Megha Satyanarayana

Biotech

Trying to keep up with all the biotech news out of China? Try these 10 must-follow Twitter accounts

By Rebecca Robbins

Biotech

What you need to know about the cholesterol trial that could swing billions

By Damian Garde

Biotech

Nine things to know about Sangamo Therapeutics and its first-in-human genome editing study

By Adam Feuerstein

Health

How to pay for CAR-T: A conversation with health policy expert Peter Bach

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Biotech

A scrappy crew of biotechs is working on a new wave of schizophrenia medicines

By Meghana Keshavan

Opinions Plus

Tell us what you really think: A survey on drug prices, biotech, and Alex Azar

By Elizabeth Cooney

« Previous Page

Biotech

Sign up for our Morning Rounds newsletter